HealthDay News — A smart exendin-4 (Ex4) delivery device is a promising therapeutic option for type 2 diabetes that can provide safe, long-term, and on-demand Ex4 therapy, according to a study published online in Nature Communications.

Noting that delivery of therapeutic peptides for diabetes therapy is compromised by short half-lives of drugs, Wei Chen, PhD, from Sun Yat-sen University Cancer Center in Guangzhou, China, and colleagues examined the role of a smart Ex4 delivery device based on microneedle (MN)-array patches integrated with dual mineralized particles that separately contain Ex4 and glucose oxidase (GOx) for diabetes therapy.

The researchers found that as a result of the differential response to the microenvironment induced by biological stimuli, the dual mineralized particle-based system can specifically release Ex4 while immobilizing GOx. Thereby the system allows glucose-responsive and closed-loop release to significantly improve the therapeutic performance of Ex4.

The mechanical strength of alginate-based MN can be enhanced by integration of mineralized particles by crosslinking to facilitate skin penetration, supporting transdermal administration that is painless and noninvasive.


Continue Reading

“We believe this smart glucose-responsive Ex4 delivery holds great promise for type 2 diabetes therapy by providing safe, long-term, and on-demand Ex4 therapy,” the authors write.

Related Articles

Reference

Chen W, Tian R, Xu C, et al. Microneedle-array patches loaded with dual mineralized protein/peptide particles for type 2 diabetes therapy. Nat Commun. 2017; 8(1):1777.